[No authors listed] Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998 Nov 5, 339(19), 1349-1357. [PMID]: 9841303.

Colquhoun D, Keech A, Hunt D, Marschner I, Simes J, Glasziou P, White H, Barter P, Tonkin A; For the LIPID Study Investigators. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. Eur Heart J. 2004 May, 25(9), 771-777. [PMID]: 15120888.

LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet. 2002 Apr 20, 359(9315), 1379-1387. [PMID]: 11978335.